Weijuan Li, MD
Cardiovascular Disease · Lynchburg, VANPI 1366881518
Payments from drug & device makers
Across 48 payments — averaging $93.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abbott$2K
- Boston Scientific$141
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$123
- Impulse Dynamics (USA) Inc.$63
- Cardiva Medical, Inc.$34
- plus $65 from 3 others
What the payments were for
- Travel & lodging$2,62458%
- Food & beverage$1,86842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 10 | $2,200 |
| Abbott | 25 | $1,865 |
| Boston Scientific | 2 | $141 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $123 |
| Impulse Dynamics (USA) Inc. | 1 | $63 |
| Cardiva Medical, Inc. | 1 | $34 |
| Novo Nordisk | 1 | $24 |
| Amgen | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,492 in reported general payments places this provider in the 65th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 246 | $266,686 |
| EntrestoSacubitril/Valsartan | 104 | $158,016 |
| Repatha SureclickEvolocumab | 116 | $95,695 |
| FarxigaDapagliflozin Propanediol | 79 | $93,419 |
| JardianceEmpagliflozin | 33 | $49,379 |
| XareltoRivaroxaban | 37 | $48,181 |
| Praluent PenAlirocumab | 41 | $24,999 |
| VascepaIcosapent Ethyl | 17 | $7,866 |
| Metoprolol Succinate | 310 | $4,682 |
| Atorvastatin Calcium | 422 | $4,172 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $2,378 |
| Rosuvastatin Calcium | 181 | $2,260 |
| Potassium Chloride | 55 | $1,712 |
| Carvedilol | 224 | $1,694 |
| Torsemide | 61 | $1,342 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lynchburg
- Thomas MeyerLynchburg$179K
- Tariq HaddadFalls Church$8M
- David LimCharlottesville$6M
- Hamid TaheriManassas$4.9M
- Philip OdonnellWinchester$4.6M
- Antonio AbbateCharlottesville$4M
- George VetrovecRichmond$2.3M
- Henry TranFalls Church$1.6M
- John SchmedtjeRoanoke$1.4M
- Jonathan LindnerCharlottesville$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.